HER2陽性乳腺癌新輔助化療方案

方案Ⅰ　曲妥珠單抗聯(lián)合化療vs單純化療

方案評(píng)價(jià)

（安　欣　史艷俠）

參考文獻(xiàn)

［1］ GIANNI L，EIERMANN W，SEMIGLAZOV V，et al.Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone，in patients with HER2-positive locally advanced breast cancer（the NOAH trial）:a randomised controlled superiority trial with a parallel HER2-negative cohort.Lancet，2010，375（9712）:377-384.

方案Ⅱ　帕妥珠單抗、曲妥珠單抗雙靶聯(lián)合化療

方案評(píng)價(jià)

（安　欣　史艷俠）

參考文獻(xiàn)

［1］ GIANNI L，PIENKOWSKI T，IM YH，et al.5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced，inflammatory，or early-stage HER2-positive breast cancer（NeoSphere）:a multicentre，open-label，phase 2 randomised trial.Lancet Oncol，2016，17（6）:791-800.

方案Ⅲ　曲妥珠單抗、帕妥珠單抗雙靶與不同化療方案聯(lián)合

方案評(píng)價(jià)

（安　欣　史艷俠）

參考文獻(xiàn)

［1］ SCHNEEWEISS A，CHIA S，HICKISH T，et al.Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer:a randomized phaseⅡ cardiac safety study（TRYPHAENA）.Ann Oncol，2013，24（9）:2278-2284.

方案Ⅳ　曲妥珠單抗+帕妥珠單抗雙靶聯(lián)合含蒽環(huán)方案vs 非含蒽環(huán)方案

（安　欣　史艷俠）

參考文獻(xiàn)

［1］ VAN RAMSHORST MS，VAN DER VOORT A，VAN WERKHOVEN ED，et al.A phaseⅢ trial of neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2-blockade for HER2+ breast cancer:The TRAIN-2 study.J Clin Oncol，2017，35S:p.ASCO#507.